

COHORTE ANRS CO13 HEPAVIH 2010-2017 PUBLICATIONS

(August 30th 2018)

I. Publications de la cohorte (n=40)

Articles cliniques (n=15)

1. Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miallhes P, et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-coinfected patients - French ANRS CO13 HEPAVIH cohort. *Journal of hepatology*. 2017.
2. Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miallhes P, et al. All-oral DAA regimens in HIV-HCV coinfecting cirrhotic patients are efficient and safe. Real-life results from the prospective ANRS CO13 - HEPAVIH cohort. *Clin Infect Dis*. 2016.
3. Salmon D SP, Gilbert C, Bani-Sadr F, Rosenthal E, Poizot-Martin I, Katlama C, Lacombe K, Gervais A, Duvivier C, Lascoux c, Neau D, Chas J, Dominguez S, Morlat P, Loko MA, Carrieri P, Dabis F and Wittkop L. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients. *Aids*. 2015;29(14):1821-30.
4. Salmon D, Bani-Sadr F, Gilbert C, Rosenthal E, Valantin MA, Simon A, et al. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. *J Clin Virol*. 2015;73:32-5.
5. Bani-Sadr F, Loko MA, Pambrun E, Winnock M, Carrieri P, Gilbert C, et al. Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfecting patients: possible role of the hepatitis C virus sustained viral response. *Aids*. 2014;28(8):1155-60.
6. Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Carrieri P, Neau D, et al. Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions. *HIV Med*. 2013;14(7):430-6.
7. Trimoulet P, Merchadou L, Winnock M, Loko MA, Fleury H, Salmon D, et al. Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples? *J Virol Methods*. 2012;181(1):131-3.
8. Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S, et al. Ribavirin and abacavir drug interaction in HIV-HCV coinfecting patients: fact or fiction? *Aids*. 2012;26(17):2193-9.
9. Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, et al. Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). *BMC Health Serv Res*. 2012;12:59.
10. Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. *Journal of hepatology*. 2012;56(4):862-8.
11. Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, et al. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort. *Antivir Ther*. 2012;17(7):1335-43.
12. Abravanel F, Raymond S, Pambrun E, Winnock M, Bonnard P, Sogni P, et al. HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients. *PLoS One*. 2012;7(11):e50289.
13. Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Lascoux-Combe C, Garipuy D, et al. Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination. *Vaccine*. 2011;29(47):8656-60.
14. Loko MA, Bani-Sadr F, Winnock M, Lacombe K, Carrieri P, Neau D, et al. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. *J Viral Hepat*. 2011;18(7):e307-14.
15. Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. *BMC Infect Dis*. 2010;10:303.

Articles Sciences Sociales (n=25)

1. Yaya I CM, Marcellin F, Miaillhes P, Wittkop L, Salmon-Ceron D, Carrieri MP; Agence Nationale de Recherches sur le Sida et les Hépatites virales B et C (ANRS) CO13 HEPAVIH (hepatitis + VIH [= HIV in French]) Study Group. Gender, Alcohol Use, and Fibrosis in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Individuals. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2018;66(6):2.
2. Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B, et al. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. *PloS one*. 2018;13(7):e0199874.
3. Yaya I, Marcellin F, Costa M. Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort). 2018;10(6).
4. Nordmann S VA, Roux P, Esterle L, Spire B, Marcellin F, Salmon-Ceron D, Dabis F, Chas J, Rey D, Wittkop L, Sogni P, Carrieri P; ANRS CO13 HEPAVIH Study Group. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVH). *Journal of viral hepatitis*. 2018;25(2):8.
5. Marcellin F MP, Wittkop L, Salmon-Ceron D, Carrieri MP. Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance. *Journal of viral hepatitis*. 2018;25(3):2.
6. Yaya I, Roux P, Marcellin F, Salmon-Ceron D, Carrieri MP. Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort). *Digestive diseases and sciences*. 2017.
7. Marcellin F, Protopopescu C, Esterle L, Wittkop L, Piroth L, Aumaitre H, et al. Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVH). *European journal of gastroenterology & hepatology*. 2017.
8. Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, et al. Significant reductions in alcohol use after Hepatitis C treatment: Results from the French ANRS CO13-HEPAVH cohort. *Addiction (Abingdon, England)*. 2017.
9. Carrieri MP, Protopopescu C, Marcellin F, Wittkop L, Lacombe K, Esterle L, et al. The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. *Journal of hepatology*. 2017.
10. Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, et al. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. *Journal of hepatology*. 2017.
11. Michel L, Lions C, Winnock M, Lang JP, Loko MA, Rosenthal E, et al. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS) HEPAVIH CO13 cohort]. *HIV medicine*. 2016.
12. Marcellin F, Protopopescu C, Poizot-Martin I, Miaillhes P, Esterle L, Wittkop L, et al. Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVH cohort). *European journal of gastroenterology & hepatology*. 2016.
13. F Marcellin CL, Eric Rosenthal, P Roux, P Sogni, L Wittkop, C Protopopescu, B Spire, D Salmon-Céron, F Dabis, P Carrieri, and the HEPAVIH ANRS CO13 Study Group. No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVH French cohort). *Drug Alcohol Rev* 2016.
14. Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, et al. Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2015;61(1):40-8.
15. Roux P, Lions C, Cohen J, Winnock M, Salmon-Ceron D, Bani-Sadr F, et al. Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVH cohort. *Antiviral therapy*. 2014;19(2):171-8.
16. Marcellin F, Roux P, Winnock M, Lions C, Dabis F, Salmon-Ceron D, et al. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. *Expert review of gastroenterology & hepatology*. 2014;8(4):351-8.
17. Marcellin F, Roux P, Loko MA, Lions C, Caumont-Prim A, Dabis F, et al. High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2014;59(8):1190-2.
18. Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, et al. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. *Journal of hepatology*. 2014;60(1):46-53.

19. Marcellin F, Lions C, Winnock M, Salmon D, Durant J, Spire B, et al. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ANRS CO13 cohort). *Addiction* (Abingdon, England). 2013;108(7):1250-8.
20. Roux P, Fugon L, Winnock M, Salmon-Ceron D, Lacombe K, Sogni P, et al. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfecting patients: one more argument for expanded access to HCV treatment for injecting drug users. *Addiction* (Abingdon, England). 2012;107(1):152-9.
21. Carrieri MP, Sogni P, Cohen J, Loko MA, Winnock M, Spire B. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfecting patients (HEPAVIH ANRS CO-13). *Hepatology* (Baltimore, Md). 2012;56(5):2010.
22. Carrieri MP, Cohen J, Salmon-Ceron D, Winnock M. Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH. *Journal of hepatology*. 2012;56(3):745-7.
23. Roux P, Cohen J, Lascoux-Combe C, Sogni P, Winnock M, Salmon-Ceron D, et al. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. *Drug and alcohol dependence*. 2011;116(1-3):228-32.
24. Michel L, Villes V, Dabis F, Spire B, Winnock M, Loko MA, et al. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepaviih, France, 2006-2008. *Journal of viral hepatitis*. 2010;17(9):650-60.
25. Carrieri MP, Cohen J, Winnock M, Salmon D. Chocolate intake, depression, and clinical progression in HIV-HCV coinfecting patients: still more questions than answers. *Archives of internal medicine*. 2010;170(17):1607; author reply 8-9.

II. Publications dans le cadre de collaborations (n=17)

1. Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R, Salmon-Ceron D, Samuel D, Seror O, Nahon P, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 Prethevic, ANRS CO13 HepaVih and ANRS CO12 CirVir Study Groups. Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. *Liver Int*. 2018 Jun 27. doi: 10.1111/liv.13921 2018.
2. Lacombe K, Fontaine H, Dhiver C, Metivier S, Rosenthal E, Antonini T, et al. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfecting Patients With Advanced Liver Disease in a French Early Access Cohort. *Journal of acquired immune deficiency syndromes (1999)*. 2017;75(1):97-107.
3. del Amo J LS, Dray-Spira R, Wittkop L, Monge S, Braun D, Vehreschild J, Teira R, Campbell C, d'Arminio Monforte A, Zangerle R, Ghosen J, Kourkounti S, Dabis F, Leport C, Meyer L, Termote M, Kirk O, Porter K, Spire B, Chene G, Egger M. Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. *AIDS* (London, England). 2017;31(2):253-62.
4. Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, et al. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. *PloS one*. 2017;12(4):e0173893.
5. Ulveling D, Le Clerc S, Cobat A, Labib T, Noirel J, Laville V, et al. A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients. *Hepatology*. 2016.
6. Nasta P, Salmon D, d'Arminio Monforte A, Pimenta JM, Cerini C, Giralda M, et al. Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study. *HIV clinical trials*. 2016;17(3):96-108.
7. Smit C, Arends J, Peters L, Montforte A, Dabis F, Zangerle R, et al. Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord. *BMC Infect Dis*. 2015;15:498.
8. Mocroft A, Lundgren J, Antinori A, Monforte A, Brannstrom J, Bonnet F, et al. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. *Euro Surveill*. 2015;20(47).
9. Miaillhes P, Gilbert C, Lacombe K, Arends JE, Puoti M, Rockstroh JK, et al. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfecting patients. *Liver international : official journal of the International Association for the Study of the Liver*. 2015;35(9):2090-9.
10. Lewin M, Gelu-Simeon M, Ostos M, Boufassa F, Sobesky R, Teicher E, et al. Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfecting with Human Immunodeficiency Virus and Hepatitis C Virus. *Radiology*. 2015;277(2):443-53.

11. EuroCoord* MeaTMWGoBoCi. Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. *Lancet HIV*. 2015;2(12):e540-9.
12. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. *AIDS (London, England)*. 2014;28(8):1181-91.
13. Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, et al. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfecting patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. *HIV Med*. 2014;15(1):30-9.
14. Cales P, Boursier J, Ducancelle A, Oberti F, Hubert I, Hunault G, et al. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. *Liver international : official journal of the International Association for the Study of the Liver*. 2014;34(6):907-17.
15. Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, et al. The incidence of AIDS-defining illnesses at a current CD4 count \geq 200 cells/ μ L in the post-combination antiretroviral therapy era. *Clin Infect Dis*. 2013;57(7):1038-47.
16. Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, et al. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavir and CO12 Cirvir). *Clin Res Hepatol Gastroenterol*. 2012;36(3):214-21.
17. Cales P, Halfon P, Batisse D, Carrat F, Perre P, Penaranda G, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. *Journal of hepatology*. 2010;53(2):238-44.